Cynata Therapeutics Crescita futura

Future criteri di controllo 2/6

Si prevede che Cynata Therapeutics aumenterà gli utili e i ricavi rispettivamente del 34.1% e 70.4% all'anno, mentre si prevede che l'EPS crescerà del 54.2% all'anno.

Informazioni chiave

34.1%

Tasso di crescita degli utili

54.2%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	36.5%
Tasso di crescita dei ricavi	70.4%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	05 Aug 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:51S - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2026	7	-5	-4	-4	1
6/30/2025	1	-8	-8	-8	1
6/30/2024	2	-10	-10	-10	N/A
3/31/2024	2	-12	-11	-11	N/A
12/31/2023	2	-14	-12	-12	N/A
9/30/2023	2	-14	-13	-13	N/A
6/30/2023	2	-14	-14	-14	N/A
3/31/2023	2	-12	-12	-12	N/A
12/31/2022	3	-9	-10	-10	N/A
9/30/2022	5	-7	-7	-7	N/A
6/30/2022	8	-5	-3	-3	N/A
3/31/2022	8	-5	-2	-2	N/A
12/31/2021	8	-4	-1	-1	N/A
9/30/2021	5	-6	-3	-3	N/A
6/30/2021	2	-8	-5	-5	N/A
3/31/2021	2	-7	-5	-5	N/A
12/31/2020	3	-6	-5	-5	N/A
9/30/2020	5	-5	-4	-4	N/A
6/30/2020	7	-4	-3	-3	N/A
3/31/2020	6	-6	-5	-5	N/A
12/31/2019	4	-8	-7	-7	N/A
9/30/2019	3	-8	-7	-7	N/A
6/30/2019	1	-8	-7	-7	N/A
3/31/2019	1	-7	-6	-6	N/A
12/31/2018	1	-6	-5	-5	N/A
9/30/2018	1	-5	-4	-4	N/A
6/30/2018	1	-5	-4	-4	N/A
3/31/2018	1	-5	N/A	-4	N/A
12/31/2017	1	-5	N/A	-5	N/A
9/30/2017	2	-5	N/A	-4	N/A
6/30/2017	2	-5	N/A	-4	N/A
3/31/2017	2	-4	N/A	-3	N/A
12/31/2016	2	-3	N/A	-2	N/A
9/30/2016	1	-4	N/A	-3	N/A
6/30/2016	1	-5	N/A	-4	N/A
3/31/2016	1	-5	N/A	-4	N/A
12/31/2015	1	-5	N/A	-4	N/A
9/30/2015	1	-4	N/A	-4	N/A
6/30/2015	0	-4	N/A	-3	N/A
3/31/2015	0	-3	N/A	-2	N/A
12/31/2014	0	-3	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-3	N/A	-2	N/A
3/31/2014	0	-3	N/A	-1	N/A
12/31/2013	0	-2	N/A	-1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che 51S rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che 51S rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che 51S rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 51S ( 70.4% all'anno) crescerà più rapidamente del mercato German ( 5.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 51S ( 70.4% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 51S è previsto essere elevato tra 3 anni

Cynata Therapeutics Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024

New major risk - Financial position

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial

Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001

New major risk - Revenue and earnings growth

Cynata Therapeutics Limited Announces Resignation of David Atkins as Director

New major risk - Financial position

Cynata Therapeutics Limited Announces Management Appointments

Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical Trial

Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCs

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Cynata Therapeutics Limited Receives Notice of Allowance for Australia & Canada Cymerus Patents

Cynata Therapeutics Limited Announces Successful Completion of Planned DSMB Review of DFU Trial

Cynata Therapeutics Limited, Annual General Meeting, Nov 22, 2022

Cynata Therapeutics Limited Receives Grant Award to Fund Study of Cynata Mscs in Heart Disease from Australian Government National Health and Medical Research Council

Cynata Therapeutics Limited Appoints Janine Rolfe as Independent Non-Executive Director, Effective 1 September 2022

Cynata Therapeutics Limited Announces Preclinical Study Showing Optimisation of CymerusTM MSCs for Coronary Artery Disease Published in Leading Peer-Reviewed Journal

Cynata Therapeutics Limited Receives Notice of Allowance from US Patent Office for Use of the Cymerus MSCs in Asthma

Cynata Therapeutics Limited Announces the Completion of A Pre-Clinical Study That Has Provided Further Evidence in Support of the Highly Potent Anti-Inflammatory Effects of Cynata's Proprietary Cymerus MSCs

Cynata Therapeutics Limited Adds New Site for MEMD Clinical Trial

United States Food and Drug Administration Clears IND for Cynata Therapeutics Limited's Phase 2 Clinical Trial of CYP-001 in GvHD

Cynata Therapeutics Limited Advances Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Cynata Therapeutics Limited Commences DFU Clinical Trial

Cynata Therapeutics Limited Receives Approval by the Central Adelaide Local Health Network Human Research Ethics Committee to Commence A Clinical Trial

Cynata Therapeutics Limited Progresses Toward Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Announces First Patient Enrolled in Cynata Mend Clinical Trial

Cynata Therapeutics Limited to Investigate New Study of the High Potency of Cymerus MSCs

New 90-day low: €0.36

New 90-day low: €0.39

Cynata Therapeutics Limited Announces Phase 3 Osteoarthritis Clinical Trial Commences

Cynata Therapeutics Limited Announces Positive Efficacy Data from A Study of Cymerustm Mesenchymal Stem Cells

New 90-day high - €0.57

New 90-day high - €0.49

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita